Limits...
Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, Xu SS - Br. J. Cancer (2015)

Bottom Line: An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls.A threshold expression value (2.259) was chosen from receiver operator characteristic curves (ROC), and the low and high miR-210 expression groups were analysed by multivariate Cox proportional hazard regression and Kaplan-Meier analyses.Results revealed an association of high serum miR-210 expression with tumour grade and poor patient outcome (P-values <0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, First Affiliated Hospital of Wannan Medical College, 2 West Zheshan Road, Wuhu City 241001, China.

ABSTRACT

Background: MicroRNA-210 (miR-210) is an oncogenic miRNA previously associated with prognosis in human gliomas, an incurable tumour type of the central nervous system. Here miR-210 was investigated as a potential serum biomarker in the diagnosis and prognosis of glioma.

Methods: Serum was immediately prepared from blood samples collected from patients with glioma grades I-IV at primary diagnosis (n=136) and healthy controls (n=50) from February 2007 to March 2014 in the Department of Neurosurgery of the First Affiliated Hospital of Wannan Medical College (Wuhu, China). Total RNA was isolated from serum. cDNA was synthesised with primers specific for miR-210 and miR-16-1 (internal control), and quantitative real-time RT-PCR was performed. Results were statistically analysed to determine the role of miR-210 in the diagnosis and prognosis of human glioma patients.

Results: An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls. A threshold expression value (2.259) was chosen from receiver operator characteristic curves (ROC), and the low and high miR-210 expression groups were analysed by multivariate Cox proportional hazard regression and Kaplan-Meier analyses. Results revealed an association of high serum miR-210 expression with tumour grade and poor patient outcome (P-values <0.001).

Conclusions: Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.

Show MeSH

Related in: MedlinePlus

MiR-210 is increased in serum from glioblastoma patients relative to healthy controls. Initial screening for miR-210 expression in the training phase, using a small subset of serum specimens from glioma patients. Box plots are shown for miR-210 levels in serum from normal control subjects (n=10) and glioblastoma patients (n=10). Boxes represent interquartile range, and the horizontal line across each box represents the median value. The y axis (log10 scale) represents relative expression of miR-210 where the data were normalised to miR-16-1 expression in sera. Statistical analysis was performed using Mann–Whitney U tests. ***P<0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4385967&req=5

fig1: MiR-210 is increased in serum from glioblastoma patients relative to healthy controls. Initial screening for miR-210 expression in the training phase, using a small subset of serum specimens from glioma patients. Box plots are shown for miR-210 levels in serum from normal control subjects (n=10) and glioblastoma patients (n=10). Boxes represent interquartile range, and the horizontal line across each box represents the median value. The y axis (log10 scale) represents relative expression of miR-210 where the data were normalised to miR-16-1 expression in sera. Statistical analysis was performed using Mann–Whitney U tests. ***P<0.001.

Mentions: To determine the feasibility of miR-210 detection in serum, quantitative analysis of miR-210 and miR-16-1 were first performed on a subset of serum samples (n=10) from patients with GBM, the most aggressive form of glioma, and serum samples (n=10) prepared from the blood of healthy control subjects. Not only was miR-210 detectable by qRT-PCR in cDNA synthesised from a small volume of serum (400 μl), but an approximately seven-fold difference in expression levels was also evident. The increased expression level of miR-210 in GBM samples relative to control samples was statistically significant (P<0.001; Figure 1).


Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, Xu SS - Br. J. Cancer (2015)

MiR-210 is increased in serum from glioblastoma patients relative to healthy controls. Initial screening for miR-210 expression in the training phase, using a small subset of serum specimens from glioma patients. Box plots are shown for miR-210 levels in serum from normal control subjects (n=10) and glioblastoma patients (n=10). Boxes represent interquartile range, and the horizontal line across each box represents the median value. The y axis (log10 scale) represents relative expression of miR-210 where the data were normalised to miR-16-1 expression in sera. Statistical analysis was performed using Mann–Whitney U tests. ***P<0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4385967&req=5

fig1: MiR-210 is increased in serum from glioblastoma patients relative to healthy controls. Initial screening for miR-210 expression in the training phase, using a small subset of serum specimens from glioma patients. Box plots are shown for miR-210 levels in serum from normal control subjects (n=10) and glioblastoma patients (n=10). Boxes represent interquartile range, and the horizontal line across each box represents the median value. The y axis (log10 scale) represents relative expression of miR-210 where the data were normalised to miR-16-1 expression in sera. Statistical analysis was performed using Mann–Whitney U tests. ***P<0.001.
Mentions: To determine the feasibility of miR-210 detection in serum, quantitative analysis of miR-210 and miR-16-1 were first performed on a subset of serum samples (n=10) from patients with GBM, the most aggressive form of glioma, and serum samples (n=10) prepared from the blood of healthy control subjects. Not only was miR-210 detectable by qRT-PCR in cDNA synthesised from a small volume of serum (400 μl), but an approximately seven-fold difference in expression levels was also evident. The increased expression level of miR-210 in GBM samples relative to control samples was statistically significant (P<0.001; Figure 1).

Bottom Line: An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls.A threshold expression value (2.259) was chosen from receiver operator characteristic curves (ROC), and the low and high miR-210 expression groups were analysed by multivariate Cox proportional hazard regression and Kaplan-Meier analyses.Results revealed an association of high serum miR-210 expression with tumour grade and poor patient outcome (P-values <0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, First Affiliated Hospital of Wannan Medical College, 2 West Zheshan Road, Wuhu City 241001, China.

ABSTRACT

Background: MicroRNA-210 (miR-210) is an oncogenic miRNA previously associated with prognosis in human gliomas, an incurable tumour type of the central nervous system. Here miR-210 was investigated as a potential serum biomarker in the diagnosis and prognosis of glioma.

Methods: Serum was immediately prepared from blood samples collected from patients with glioma grades I-IV at primary diagnosis (n=136) and healthy controls (n=50) from February 2007 to March 2014 in the Department of Neurosurgery of the First Affiliated Hospital of Wannan Medical College (Wuhu, China). Total RNA was isolated from serum. cDNA was synthesised with primers specific for miR-210 and miR-16-1 (internal control), and quantitative real-time RT-PCR was performed. Results were statistically analysed to determine the role of miR-210 in the diagnosis and prognosis of human glioma patients.

Results: An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls. A threshold expression value (2.259) was chosen from receiver operator characteristic curves (ROC), and the low and high miR-210 expression groups were analysed by multivariate Cox proportional hazard regression and Kaplan-Meier analyses. Results revealed an association of high serum miR-210 expression with tumour grade and poor patient outcome (P-values <0.001).

Conclusions: Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.

Show MeSH
Related in: MedlinePlus